Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seres Therapeutics Inc
(NQ:
MCRB
)
0.9906
+0.0006 (+0.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Seres Therapeutics Inc
< Previous
1
2
3
4
Next >
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
July 22, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
July 22, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
July 01, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at JMP Securities Life Sciences Conference
June 10, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
June 10, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
June 01, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
May 25, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
May 21, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
May 20, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
May 19, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
May 12, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting
May 11, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
May 04, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021
April 28, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit
April 15, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.